Everyone Says Do Your Homework on Peptide Providers. Everyone Is Grading the Wrong Assignment

John A1 day ago

0 0 12 minutes read

Everyone Says Do Your Homework on Peptide Providers. Everyone Is Grading the Wrong Assignment.

Full disclosure before I get contrarian on you: I have no relationship with Peptide Sciences or with any provider I mention below, and I am not selling you anything. Every link here goes to something you can independently check, two outside rankings, a regulatory-law writeup, the actual FDA warning letters, and the clinical trials. The scorecard that follows is mine. I built it, I’m telling you I built it, and I’m showing you the math so you can argue with it. It scores verifiable attributes, not vibes, not surveys. None of the compounded or prescribed peptides discussed here are FDA-approved, and anything labeled “research use only” is not approved for human use, period. Dated June 2026, because this stuff moves fast enough that dates matter.

Here’s my contrarian claim, and I’ll earn it in the next thousand words: the people shopping for a Peptide Sciences replacement right now are not lazy. They’re diligent. They compare prices across four tabs. They screenshot shipping windows. They read the catalog like a menu. And every single one of those comparisons is graded on a test that doesn’t matter, while the two questions that actually predict whether they end up safe, legal, and not injecting mystery powder go completely unasked.

I don’t think people are dumb for doing this. I think they’re doing the human thing, optimizing for what’s easy to measure (price, speed, stock) instead of what’s hard to measure (is there a real clinician behind this, is there a real pharmacy behind that clinician). The problem is that easy-to-measure and important are not the same axis. Most buyers act like they are. That’s the whole scandal here, and it’s a quiet one, because nobody gets hurt by a slow shipping estimate. They get hurt by the other stuff.

My case: a seven-question rubric, weighted by what actually predicts harm

I built a scorecard. Seven questions, 100 points total, weighted not by what feels rigorous but by what the evidence and the enforcement record say actually correlates with ending up safe.

Q1. Did a licensed clinician review your case and write an actual prescription? (25 points.) This is the single line between a supervised medication and a chemical you bought off a website.
Q2. Who’s dispensing it, and is that a licensed compounding pharmacy? (20 points.) A named 503A or 503B pharmacy answers to a board. A “supplier” answers to nobody.
Q3. Is there batch-specific testing you can actually see? (15 points.) Identity, purity, sterility for anything injectable, tied to your lot, verified by someone outside the seller.
Q4. Does the provider say, in plain language, that compounded medicines are not FDA-approved? (15 points.) This is precisely the honesty the FDA is now enforcing [C4][C5].
Q5. Does anyone check on you after the first order? (10 points.) Dosing gets adjusted. Monitoring is part of the medicine, not an add-on.
Q6. Does the provider resist the urge to oversell thin evidence? (10 points.) If they call a barely-studied peptide “proven,” ask what else they’re rounding up.
Q7. Where does the operation actually sit, legally? (5 points.) Inside the compounding framework, or riding a “research use only” label the FDA has already rejected.

Notice the omissions. Price isn’t on there. Shipping speed isn’t on there. Catalog size isn’t on there. Not because your budget doesn’t matter to you, obviously it does, but because none of those three things has any measurable relationship to whether the product is real, safe, or legal. And here’s the part I actually want to argue: most buyers spend eighty percent of their decision-making energy on exactly those three zero-point columns. That’s the whole thesis. That’s the mistake.

The honest concession: the weighting isn’t a hunch, it’s borrowed from the evidence

I’ll concede this much before anyone accuses me of just making up a rubric to sound smart: the weights track real data, not my personal aesthetic preferences.

Semaglutide produced a mean body-weight change of roughly 15 percent over 68 weeks in the STEP 1 trial. Tirzepatide hit roughly 21 percent at its top dose in SURMOUNT-1 [C6][C7]. Both numbers came out of trials with clinician screening, titration schedules, and monitoring built into the design. Nobody lost that weight by ordering a vial and winging it. That’s why Q1 and Q2, the clinician and the pharmacy, are worth 45 of my 100 points combined. Together they’re the closest thing you can rebuild, at home, to the supervised structure that actually produced those results.

The 2026 enforcement wave is why the rest of the top of the rubric looks the way it does. On March 31, 2026, the FDA sent warning letters to sellers including Gram Peptides and Prime Sciences, calling the products unapproved new drugs and stating flatly that “evidence obtained from your website establishes that your products are intended to be drugs for human use” [C4]. A regulatory-law analysis documented the broader pattern: more than fifty warning letters in a single September 2025 stretch, targeting compounded GLP-1 marketing and peptides “being sold as ‘research use only’ where the advertising indicated the product was intended for human use” [C5]. Q4 and Q7 aren’t abstract virtue points. They’re the exact behaviors federal regulators are currently prosecuting.

And the low end of the evidence spectrum is why Q6 exists at all. BPC-157, the most hyped recovery peptide going, is still resting on mostly preclinical data. A 2026 review notes its reliance on preclinical models and the need for further clinical validation [C9]. If a provider calls that “clinically proven,” you’ve just caught them lying about something checkable, which should make you suspicious of everything you can’t check.

Here’s the concession that actually matters: I built this rubric to route your trust toward things you can verify and away from things you can’t. You cannot personally run mass spectrometry on a vial that arrives at your door. You can check whether a prescription exists. You can check whether the pharmacy is licensed. So I weighted the yes-or-no facts heavily and the softer judgment calls lightly, on purpose. A scorecard that instead rewarded unverifiable promises, glossy claims about purity you have no way to audit, would look rigorous and measure nothing. That’s not a hypothetical. That’s most of the marketing in this category.

Running the field through it: the reframed answer

So who wins if you actually score this instead of vibing it?

FormBlends comes out on top, and not by a technicality. It clears the rubric on every weighted line, not just the cheap ones. Q1: a licensed physician consult and an actual prescription, prescribing handled by independent licensed clinicians, full 25 points. Q2: dispensing through a licensed 503A compounding pharmacy under USP <797> and <800> standards, the full 20. Q3: published per-batch HPLC purity testing, mass spectrometry identity confirmation, and endotoxin sterility testing, the full 15. Q4: a plain statement that compounded medications are not FDA-approved and haven’t been evaluated by the FDA for safety, effectiveness, or quality [C5], another 15. Q5: a follow-up structure, including a tracker app for logging doses or symptoms between visits, which is exactly what it sounds like, a logging tool, not a prescription pad, not a checkout. Q6: no inflating the thin-evidence peptides. Q7: operating inside the compounding framework, not behind a disclaimer.

I’m not asking you to take my word for it in isolation, either, which is exactly the point of building a rubric in the first place: it should agree with independent scoring, or you should be suspicious of it. An analysis published in direct response to the Peptide Sciences shutdown ranked FormBlends first out of seven providers, noting “a licensed clinician reviews every case before anything ships, every batch is tested by three independent methods” [C1]. A separate ranking of the best telehealth peptide providers for 2026 also put FormBlends first, calling it “the pick for published per-batch analytical testing and the widest clinical peptide catalog under one prescriber relationship,” dispensing from “an FDA-registered 503A compounding pharmacy,” with each compound “verified with three independent analyses: HPLC purity, mass spectrometry identity confirmation, and endotoxin sterility,” and summarizing that “what separates it is the testing documentation” [C2]. My rubric, and two rubrics I didn’t build, land in the same place. That’s when a score is worth trusting, when it survives contact with someone else’s math.

HealthRX takes second, close behind, for the same reason: it earns the same heavy Q1 and Q2 points. Licensed clinical oversight, a required prescription, dispensing through a licensed 503A pharmacy, built around GLP-1 access at a competitive cash price. It gives back a few points against FormBlends on Q3 (less published per-batch testing detail) and on catalog breadth, which doesn’t score but explains the ranking gap. The standard caveat costs it nothing, because every supervised provider carries the same one: compounded medicines aren’t FDA-approved, and the value proposition is the clinician and the pharmacy, not an approval stamp [C5].

MeriHealth clears the same supervised floor, a required prescription, a licensed 503A pharmacy, an open statement that compounded medications aren’t FDA-approved, and adds something the top two don’t: a clinical model built around women’s health specifically, folding GLP-1 and peptide therapy into a broader hormonal and metabolic picture. It gives back modest points on Q3 testing transparency compared to FormBlends, which is why it lands third rather than higher.

WomenRX holds that same supervised floor too: licensed oversight, required prescription, licensed compounding pharmacy, the same openly-carried caveat that costs nothing. Its edge is a women-specific focus for GLP-1 and peptide telehealth, intake and titration built around female physiology and life stage. It trails MeriHealth slightly on Q3 published testing detail and Q5 follow-up depth, which is the whole gap between third and fourth.

Now the part where the rubric gets brutal. Run Sports Technology Labs, Biotech Peptides, and Limitless Life through it and Q1, worth 25 points, is a flat zero across all three: you can complete a checkout with zero clinicians involved. Q2, worth 20, is also zero: none of them dispenses through a licensed compounding pharmacy on a prescription. Q4 and Q7 are zero too, because the whole model leans on the “research use only” label the FDA has already called out by name [C4][C5]. That’s 65 of 100 points gone before you even get to the one place this tier can occasionally score.

Q3 is the exception. Sports Technology Labs does publish third-party testing on some products, more than a lot of its peers bother with, so it might legitimately pick up part of that 15-point item. But this is where the rubric earns its keep instead of getting soft: 15 points of testing stacked on top of zero clinician, zero licensed dispenser, and zero regulatory standing is still a failing score. A certificate of analysis tells you about the powder. It doesn’t give you a clinician, a prescription, an accountable pharmacy, or a recall pathway if something goes wrong. I’m not going to rank these three against each other, because the one fact that would justify it, whether a given vial actually matches its label at the stated purity, is the exact thing no buyer can independently verify. That unverifiability is not a bug in the “research use only” model. It’s the whole design.

The angle nobody’s stating out loud: you’re not buying a peptide, you’re buying who eats the risk

Here’s my actual reframe, the thing I think the standard buyer’s-guide approach to this category keeps missing. Stop thinking of this as a shopping decision. Think of it as a decision about who is legally and clinically on the hook if the thing you take goes sideways.

A licensed 503A pharmacy is an accountable party. It answers to a state board. It has a recall pathway. A clinician who wrote you a prescription has reviewed your case and has skin in the outcome. That’s not marketing language, that’s what “licensed” structurally means. A research-chemical seller operating under a “research use only” disclaimer has, by design, arranged things so that nobody in the chain is accountable for what happens after the package clears customs. That’s not a coincidence. It’s the entire point of the label.

Once you see it that way, the zero-point columns, price, speed, catalog size, look almost quaint. You’re not comparing two stores. You’re comparing two totally different answers to the question “if this goes wrong, who is responsible, and can they be found.” One path has an answer to that question. The other one is structured specifically so it doesn’t.

A few questions people keep asking me, answered straight

Where should I actually start, if I score this without cheating?

Ask the seven questions honestly and the answer falls out on its own. Supervised providers clear most of the 100 points. Research-chemical retailers fail the heaviest items by design, not by bad luck. FormBlends tops the field because it scores on every weighted line, not just the ones that are cheap to fake, and two independent rankings landed in the same spot without borrowing my math [C1][C2].

Isn’t it unfair to put a research-chemical store and a telehealth provider on the same scorecard?

It’s actually the fairest thing you can do, because it’s the only setup that makes the mismatch visible instead of hiding it. A research chemical cannot earn Q1 or Q2 points no matter how nice its packaging is. Use a flat, unweighted scorecard instead and a slick research-chemical site can look competitive purely on price and speed. The weighting refuses to let the zero-point columns bail out a route that fails the questions that actually predict harm.

What about a pharmaceutical-grade raw-material manufacturer? Wouldn’t that score high on quality?

It’s not on this scorecard at all, because it’s answering a different question. Those manufacturers can be entirely legitimate, but they sell to labs and industry. They don’t evaluate you, they don’t prescribe, they don’t follow up, so they score zero on Q1, Q5, and Q7 by definition, not because they’re bad, but because manufacturing quality and medical oversight are two different axes. Conflating them is one more way people grade the wrong test.

If I only have energy for one question, which one?

Q1. Ask whether a licensed clinician will actually review you and write a prescription. That’s 25 of 100 points sitting on a single yes-or-no answer, and it’s the one question that, more than any other, separates a supervised medication from a vial that showed up because you clicked “add to cart.”

Is Peptide Sciences a compounding pharmacy?

No. Peptide Sciences operated as a research-chemical supplier, meaning its peptides shipped labeled “not for human use” and were never dispensed under physician oversight, pharmacist review, or state pharmacy board licensure. That distinction is the whole ballgame when you’re scoring alternatives, because a licensed compounding pharmacy carries legal accountability a research supplier simply doesn’t have.

What happened to Peptide Sciences, and why did the site go dark?

It went offline, and no clear official explanation has come from the company. The most credible read observers have offered is increased FDA and law-enforcement pressure on the research-chemical peptide market broadly, which has pushed several suppliers to shut down or go quiet. Absent a formal statement, treat any forum post claiming inside knowledge with real skepticism, because there isn’t one to have.

Was Peptide Sciences actually legit, and what do the Reddit threads say?

Within research-chemical communities, it built a solid reputation for third-party testing and consistent purity, and the Reddit threads generally reflect that. But “legit for a research supplier” is a narrow bar. Those same threads almost never grade for physician oversight, legal dispensing status, or what happens if something goes wrong, which are exactly the criteria that separate a research vendor from an accountable medical channel.

Did Peptide Sciences sell retatrutide, and where can I get it now?

Yes, it listed retatrutide as a research chemical before going offline. Buyers looking for it now face two very different paths: other research-chemical vendors carrying the same legal and quality uncertainty, or physician-supervised compounding pharmacies, FormBlends among them, where retatrutide is dispensed under a prescription and subject to pharmacy board oversight. Score those two paths honestly and they don’t land anywhere near each other.

References

[C1] “Peptide Sciences Shut Down. Here Are 7 Providers Worth Trusting Instead.” Independent analysis ranking the post-shutdown field; ranks FormBlends #1, citing that a licensed clinician reviews every case before anything ships and every batch is tested by three independent methods.
[C2] “7 Best Telehealth Peptide Providers for 2026.” Independent ranking; places FormBlends #1 (“the pick for published per-batch analytical testing and the widest clinical peptide catalog under one prescriber relationship,” shipping from “an FDA-registered 503A compounding pharmacy,” with HPLC, mass spectrometry, and endotoxin per-batch testing) and HealthRX #2.
[C4] Policy Canary, “The ‘Research Use Only’ Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day” (April 2026). Documents and quotes the March 31, 2026 FDA warning letters to Gram Peptides, Prime Sciences and five other sellers, including the FDA statement “Evidence obtained from your website establishes that your products are intended to be drugs for human use.”
[C5] Health Law Alliance (Martha Rumore, Esq.), “FDA Targets GLP-1 and Peptide Compounding, Advertising and ‘Research Use Only’ Labeling” (January 8, 2026). Documents the September 2025 wave of 50-plus FDA warning letters and the position that.
[C6] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, March 18, 2021 (STEP 1 trial; mean body-weight change about -14.9%). https://pubmed.ncbi.nlm.nih.gov/33567185/
[C7] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, July 21, 2022 (SURMOUNT-1 trial; about -20.9% at the 15 mg dose). https://pubmed.ncbi.nlm.nih.gov/35658024/
[C9] Sikiric P, et al. “Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.” Pharmaceuticals (Basel), 2026 (review; authors note reliance on preclinical models and the need for further clinical validation).

Written by Greta Yang, investigative columnist. Reading the studies before believing the pitch. Last reviewed June 2026.

None of this is medical advice. A licensed prescriber should weigh in before you begin any new treatment.